Winning XOMA Stock Forecast: Xoma Corporation Jumped Up By 269.14% in 1 Year

“We made significant progress on multiple fronts executing our new business strategy, and in doing so we completely transformed the Company. The highlight events were clearly the license agreements we secured for both gevokizumab and our IL-1 beta intellectual property portfolio with Novartis. Our strategy was further reinforced with new license agreements for use of our proprietary phage display libraries for antibody discovery.”

– Jim Neal, Chief Executive Officer of XOMA

[Image Source: http://www.scienceimage.csiro.au/image/2057, from Wikimedia Commons]

Over the last 12 months, the market has witnessed a huge surge of XOMA’s stock by 269.14%. The result can be illustrated in the below chart:

The remarkable gain of XOMA can be attributed to the strong performance of the company in Q2 and Q3 2017. In Q2 2017, XOMA reached the $10 million milestone due to the license agreement with Novartis (NYSE: NVS). Additionally, thanks to the XOMA 052 License Agreement and IL-1 Target License Agreement with Novartis, XOMA has recognized $35.4 million revenue in license and collaborative fee in Q3 2017. As a result, over the last 5 quarters, Q2 and Q3 2017 are the only two quarters with a positive net income, $0.285 million and $26.344 million respectively.

(Source: financials.morningstar.com)

On May 25, 2017, I Know First has issued a bullish 1-year prediction for XOMA Corporation with the signal of 84.71 and the predictability of 0.52. One year later, XOMA shot up to $24.88 (269.14% upside), in line with our forecast.

Current I Know First subscribers received this bullish ESND forecast on May 25, 2017.

To subscribe today click here.

How to interpret this diagram

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.

XOMA Corporation (NASDAQ: XOMA) is a biotechnology company located in Delaware. The company uses its own unique platform of antibody technologies to discover and develop innovative therapeutics. XOMA’s business model is to license its therapeutic assets to other corporations, which is later responsible for later development, approval, or commercialization. Moreover, the company has also licensed its platform of antibody technologies to other companies who want to make their own discovery efforts. The main customers of XOMA include pharmaceutical and biotech companies such as Novartis International Pharmaceutical Ltd. (“Novartis), Novo Nordisk AS (“Novo Nordisk”), Takeda Pharmaceutical Company Ltd. (“Takeda”), etc. Besides that, other companies also funded more than 20 programs of XOMA, which will generate milestone and royalty payments in the future. XOMA’s asset base includes different antibodies with unique properties. These antibodies are designed to either enhance or diminish a target protein’s activity. In February 2017, XOMA achieved initial proof-of-concept (“POC”) for its X358 clinical program. In the future, the company aim to maximize the value of X358 through licensing agreements with its partners. Moreover, XOMA will focus more on developing and acquiring revenue generating assets and coupling them with the current infrastructure. XOMA also expects that the payments from the licensees will contribute a significant portion of its future revenue.

Disclaimer

Before making any trading decisions, consult the latest forecast as the algorithm updates predictions daily. You can use the algorithm for intra-day trading. The predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.